For the quarter ending 2025-09-30, YBGJ has $953,211 in assets. $2,555,316 in debts.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Due from related parties | - | 282,617 | ||
| Cash | 10,926 | 10,416 | ||
| Receivables | 114,287 | 118,006 | ||
| Prepaid expenses | 202,054 | 210,413 | ||
| Inventory | 37,889 | 37,650 | ||
| Due from related parties | 284,407 | - | ||
| Total current assets | 649,563 | 659,102 | ||
| Property and equipment, net | 84,645 | 126,007 | ||
| Intangible assets, net | 43,241 | 44,653 | ||
| Operating lease right of use asset | 138,604 | 184,943 | ||
| Lease security deposit | 37,158 | 36,863 | ||
| Total assets | 953,211 | 1,051,568 | ||
| Accounts payable and accrued expenses (including accounts payable and accrued expenses of vie without recourse to the company of 891,838 and 880,787 as of september 30, 2025 and december 31, 2024, respectively) | 957,197 | 1,050,497 | ||
| Advances from prospective customers/distributors (including advances from prospective customers/distributors of vie without recourse to the company of 448,812 and 424,026 as of september 30, 2025 and december 31, 2024, respectively) | 434,765 | 432,028 | ||
| Due to related parties (including due to related parties without recourse to the company of 874,683 and 2,741,830 as of september 30, 2025 and december 31, 2024, respectively) | 1,024,750 | 3,365,814 | ||
| Operating lease liabilities - current (including operating lease liabilities - current of vie without recourse to the company of 138,604 and 367,992 as of september 30, 2025 and december 31, 2024, respectively) | 138,604 | 177,131 | ||
| Total current liabilities | 2,555,316 | 5,025,470 | ||
| Operating lease liabilities - non-current (including operating lease liability - non- current of vie without recourse to the company of 7,812 and 110,773 as of september 30, 2025 and december 31, 2024, respectively) | 0 | 7,812 | ||
| Preferred stock, par value .01 per share, 5,000,000 shares authorized, none issued | - | 0 | ||
| Total liabilities | 2,555,316 | 5,033,282 | ||
| Common stock, value-Common Stock Class B | - | 4 | ||
| Common stock, value-Common Class A | 124,876 | - | ||
| Common stock, value-Common Stock Class A | - | 119,816 | ||
| Common stock, value-Common Class B | 4 | - | ||
| Additional paid in capital | 5,514,423 | 2,989,483 | ||
| Accumulated deficit | -7,478,641 | -7,326,775 | ||
| Accumulated other comprehensive income (loss) | 176,450 | 217,229 | ||
| Total deficit attributable to common shareholders | -1,662,888 | -4,000,243 | ||
| Non-controlling interests | 60,783 | 18,529 | ||
| Total deficit | -1,602,105 | -3,981,714 | ||
| Total liabilities and shareholders' equity | 953,211 | 1,051,568 | ||
Yubo International Biotech Ltd (YBGJ)
Yubo International Biotech Ltd (YBGJ)